Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : University of Alberta
Deal Size : Undisclosed
Deal Type : Agreement
Onco-Innovations Collaborates with Alberta for PNKP Inhibitor Cancer Research
Details : The agreement aims to expand the research scope of its second-generation nanoparticle formulation of its Polynucleotide Kinase 3'-Phosphatase Inhibitor technology to encompass hard-to-treat cancers.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 13, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : University of Alberta
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Onco-Innovations' Nanoparticle Formulation PNKP Technology Shown to Slow Tumour Growth
Details : The outcome of the study validated the potential of the PNKP Compound as a potent, single-agent therapy in combating colorectal cancer, specifically in cases where tumours exhibit PTEN deficiencies.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 14, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Onco-Innovations' Tech Enhances Cancer Radiation Therapy
Details : Onco-Innovations Limited announces exclusive licensing of PNKP inhibitors to enhance cancer treatment by targeting DNA repair mechanisms, aiming to improve radiation therapy effectiveness.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable